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ABSTRACT
Like asthma and atopic dermatitis, allergic rhinitis is an allergic disease, but of the three, it is the only type I al-
lergic disease. Allergic rhinitis includes pollinosis, which is intractable and reduces quality of life (QOL) when it
becomes severe. A guideline is needed to understand allergic rhinitis and to use this knowledge to develop a
treatment plan. In Japan, the first guideline was prepared after a symposium held by the Japanese Society of
Allergology in 1993. The current 7th edition was published in 2013, and is widely used today.
To incorporate evidence based medicine (EBM) introduced from abroad, the most recent collection of evi-
denceliterature was supplemented to the Practical Guideline for the Management of Allergic Rhinitis in Japan
2013. The revised guideline includes assessment of diagnosistreatment and prescriptions for children and
pregnant women, for broad clinical applications. An evidence-based step-by-step strategy for treatment is also
described. In addition, the QOL concept and cost benefit analyses are also addressed. Along with Allergic
Rhinitis and its Impact of Asthma (ARIA), this guideline is widely used for various clinical purposes, such as
measures for patients with sinusitis, childhood allergic rhinitis, oral allergy syndrome, and anaphylaxis and for
pregnant women. A Q&A section regarding allergic rhinitis in Japan was added to the end of this guideline.
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1. Definition and Disease Names
Allergic rhinitis is a type I allergic disease of the nasal
mucosa, characterized by paroxysmal repetitive
sneezing, watery rhinorrhea, and nasal blockage. The
disease names, most commonly used in publications,
include allergic rhinitis, nasal allergy, nasal hypersen-
sitivity, and pollinosis. Allergic rhinitis is classified
into perennial and seasonal compared to ARIA guide-
line. Pollinosis is seasonal allergic rhinitis caused by
pollen antigens, frequently complicated by allergic
conjunctivitis.1
2. Classification of Rhinitis
Rhinitis generally indicates nasal mucosal inflamma-
tion (Table 1). Histopathologically, nasal mucosal in-
flammation is an exudative inflammation. Suppurative
and allergic inflammation are particularly common.
Both are characterized by leakage of serum compo-
nents from vessels, edema, cell infiltration, and hy-
persecretion.
Infectious rhinitis is classified into acute and
chronic rhinitis. Hyperesthetic non-infectious rhinitis,
that is nasal hypersensitivity complicated by sneezing
and watery rhinorrhea, or all nasal symptoms includ-
ing sneezing, watery rhinorrhea, and nasal blockade,
is classified into allergic and nonallergic rhinitis. Non-
allergic rhinitis includes vasomotor rhinitis and rhini-
tis with eosinophilia syndrome. Vasomotor rhinitis is
symptomatically similar to allergic rhinitis. However,
it cannot be identified as an allergy by tests. The ma-
jor cause of vasomotor rhinitis is dysautonomia of the
nasal mucosa. However, this definition is not recog-
nized in international classification and vasomotor
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Fig.　1　Prevalence in 1998 and 2008. Adapted from reference 1.
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Table　1　Classifi cation of rhinitis
1. Infection
a. Acute   b. Chronic
2. Hyperesthetic non-infectious rhinitis
a. Combined type (nasal hypersensitivity):
i) Allergic: perennial rhinitis, seasonal rhinitis
ii) Nonallergic: vasomotor (idiopathic) rhinitis, rhinitis with eosinophilia syndrome
b. Rhinorrhea type: gustatory rhinitis, cold inhalation rhinitis, senile rhinitis
c. Congestive type: medicament rhinitis, psychogenic rhinitis, pregnant rhinopathia, hormonal rhinitis, and cold rhinitis
d. Dry type: dry nose
3. Irritant rhinitis
a. Physical   b. Chemical   c. Radiation
4. Others
a. Atrophic rhinitis   b. Specifi c granulomatous rhinitis
The hyperesthetic non-infectious rhinitis is characterized by hypersensitivity. However, this is not infl ammatory, except for the allergic rhi-
nitis. Thus, this should reasonably be eliminated from the classifi cation of rhinitis and regarded as a disease similar to allergy or hypersensi-
tivity diseases. However, this was placed into this classifi cation in view of potential clinical convenience. Vasomotor rhinitis is called an idio-
pathic rhinitis in international classifi cation. This term was used according to the practices. The conditions listed in 4a and 4b should be 
classifi ed under chronic rhinitis in 1b. However, they were separately classifi ed because of the small number of cases.
Adapted from reference 1.
rhinitis is classified as idiopathic rhinitis.2 Rhinitis
with eosinophilia syndrome is characterized by nasal
discharge eosinophilia, and other negative allergy
tests.3
Noninfectious, nonallergic rhinitis also includes
rhinorrhea, congestive, and dry types. Rhinorrhea
types include gustatory rhinitis. Congestive types in-
clude medicament rhinitis and psychogenic rhinitis,
pregnant rhinopathy, hormonal rhinitis, and cold
rhinitis. Medicament rhinitis is caused by the long-
term administration of sympathomimetics, vasodila-
tory antihypertensives, β-stimulatory antihyperten-
sives, bronchodilators, antidepressants, or contracep-
tive pills. However, the most common cause is the
overuse and overdose of sympathomimetic nose
drops prescribed for nasal blockage.4
3. Epidemiology of Allergic Rhinitis
The number of patients with allergic rhinitis, particu-
larly common sinusitis, has decreased since the
1960s. In contrast, the number of patients with aller-
gic rhinitis has increased. Recently, the number of pa-
tients with pollinosis, particularly with Japanese cedar
pollinosis, has markedly increased. An epidemiologi-
cal study revealed a marked increase in the preva-
lence of allergic rhinitis between 1998 and 2008 (Fig.
1).5 In particular, the number of patients with Japa-
nese cedar pollinosis has increased. Data on preva-
lence by age shows that perennial allergic rhinitis is
common among young people and that Japanese ce-
dar pollinosis is common among middle-aged people
(Fig. 2). According to the International Study of
Asthma and Allergies in Childhood (ISAAC), the
prevalence in Japan is at a medium level in the world
(Fig. 3).6
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Fig.　2　Prevalence by age. Adapted from reference 1.
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Fig.　3　Allergic rhino conjunctivitis symptoms within one year by ISAAC questionnaire (ISAAC phase I test). 
Survey in 1995 by ISAAC (The International Study of Asthma and Allergies in Childhood). The survey point in Ja-
pan is Fukuoka. Circles indicate the prevalence for each survey point (average 3,000 subjects/point).
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Fig.　4　Mechanism of allergic rhinitis. Hi, histamine; LT, leukotriene; TXA2, thromboxane A2; PGD2, prostaglan-
din D2; PAF, platelet activating factor; IL, interleukin; GM-CSF, granulocyte/macrophage colony stimulating factor; 
IFN-γ, Interferon-γ; TARC, thymus and activation-regulated chemokine; RANTES, regulated upon activation nor-
mal T expressed, and presumably secreted; TCR, T cell receptor. †Only possible migration factors are listed be-
cause no theory has been established. ‡Presumed to be caused by allergic reaction. Adapted from reference 1.
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4. Pathogenic Mechanisms of Allergic
Rhinitis (Fig. 4)
There are various diatheses for allergic rhinitis sensi-
tization, but their mechanisms remain largely un-
known. Genetic factors and diatheses for IgE anti-
body production are the most important. In response
to antigen entry into the mucous membrane, IgE anti-
bodies are produced in the nasal mucosa and re-
gional lymphatic tissues. Most causative antigens are
inhalation antigens, such as Dermatophagoides (a
major antigen in house dust), pollens (trees, grasses,
and weeds), fungi, and pets. Of these, Dermato-
phagoides and pollens are most common.
In sensitized individuals, antigens inhaled through
the nasal mucosa pass through the nasal mucosal epi-
thelial cells to bind to IgE antibodies on mast cells
distributed over the nasal mucosa. In response to an
antigen-antibody reaction, chemical mediators, such
as histamine and peptide leukotrienes (LTs), are re-
leased from mast cells. These irritate the sensory
nerve endings and blood vessels of the nasal mucosa
to cause sneezing, watery rhinorrhea, and nasal mu-
cosal swelling (nasal blockage). This is an early
phase reaction. Various inflammatory cells, such as
activated eosinophils, infiltrate into the nasal mucosa
exposed to antigens in response to cytokines, chemi-
cal mediators, and chemokines. Leukotrienes, pro-
duced by these inflammatory cells, cause nasal mu-
cosal swelling. This is a late phase reaction, seen at 6-
10 hours after antigen exposure.7
4.1. Sneezing
Sneezing is caused by histamine irritation of the sen-
sory nerve (trigeminal nerve) in the nasal mucosa,
transmitted to the sneezing center of the medulla ob-
longata. The irritant effects of histamine on the sen-
sory nerve are enhanced by allergies to cause sneez-
ing.
4.2. Watery Rhinorrhea
The sensory nerve irritation in the nasal mucosa
causes parasympathetic nerve excitement, resulting
in sneezing reflex. Acetylcholine is released from the
parasympathetic nerves. Histamine acts directly on
the nasal mucosal vessels to cause plasma leakage.
Allergic Rhinitis
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Table　2A　Classifi cation of the severity of allergic rhinitis symptoms I
Severity
Paroxysmal sneezing or rhinorrhea†
++++ +++ ++ + -
Nasal blockage
++++ Most severe Most severe Most severe Most severe Most severe
+++ Most severe Severe Severe Severe Severe
++ Most severe Severe Moderate Moderate Moderate
+ Most severe Severe Moderate Mild Mild
- Most severe Severe Moderate Mild No symptoms
Sneezing and rhinorrhea type, ; Nasal blockage type, ; Combined type, .
†Select more severe one, sneezing or rhinorrhea.
Severe, moderate, and mild symptoms are determined according to conventional classifi cation. Uncontrollable severe symptoms are clas-
sifi ed into the most severe symptoms, because they may occur during a heavy pollen dispersal period. Adapted from reference 1.
Table　2B　Classifi cation of the severity of allergic rhinitis symptoms II: severity of the symptoms
Severity
Types
++++ +++ ++ + -
Paroxysmal sneezing (Average 
number of episodes of paroxysmal 
sneezing in a day)
≥21 times 20-11 times 10-6 times 5-1 times Below +
Rhinorrhea (Average number of 
episodes of nose blowing a day) ≥21 times 20-11 times 10-6 times 5-1 times Below +
Nasal blockage Completely ob-structed all day
Severe nasal 
blockage causing 
prolonged oral 
breathing in a day
Severe nasal block-
age causing occa-
sional oral breath-
ing in a day
Nasal block-
age without 
oral breathing
Below +
Troubles with daily life† Impossible Painful and com-plicating daily life
Intermediate be-
tween (+++) and (+) Few troubles Below +
†Troubles with daily life: Troubles with work, study, household work, sleep, going out, etc.
Adapted from reference 1.
However, it accounts for only 10% of rhinorrhea. Most
rhinorrhea is secreted from the nasal glands.8
4.3. Nasal Mucosal Swelling
Nasal mucosal swelling is caused by interstitial
edema in the nasal mucosa, due to plasma leakage,
and congestion of the nasal mucosal vessels. The di-
rect actions of chemical mediators, such as hista-
mine, PAF, prostaglandin D2, kinin, and particularly
leukotriene, are essential. Leukotrienes released
from infiltrating inflammatory cells, particularly
eosinophils, play a major role in nasal mucosal swel-
ling, observed in a late phase.7-9
Thus, the early phase reaction of allergic rhinitis is
caused by an IgE antibody-mediated type I antigen-
antibody reaction. Then, infiltrating inflammatory
cells induce a late phase reaction. Continuous antigen
irritation cause chronic lesions.
5. Tests and Diagnosis of Allergic Rhinitis
5.1. Tests
Nasal eosinophil staining in the nasal secretion and
serum IgE antibody measurement are useful for diag-
nosis. Potential causative allergens should be identi-
fied based on skin reactions or serum allergen-
specific IgE antibody measurements. A nasal mucosa
provocation test can be conducted for house dust and
ragweed, but their assessments may be difficult. Rhi-
noscopy and x-ray examinations (Caldwell and Wa-
ters methods) are performed for differential diagno-
sis.
5.2. Diagnosis
A definite diagnosis is made based on three symp-
toms (sneezing and nasal itch, watery rhinorrhea,
and nasal blockade), together with positive nasal
eosinophil tests, and identified causative allergens,
based on skin reactions or serum allergen-specific
IgE antibody measurements.
Okubo K et al.
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Fig.　5　Japanese Allergic Rhinitis Standard Quality of Life Questionnaire (JRQLQ No. 1). Adapted from reference 12.
Japanese Rhino-conjunctivitis Quality of Life Questionnaire
(JRQLQ No1)
To patients with allergic rhinitis (including pollinosis)
These days, the aim of medical treatment is not just to cure
disease but also to give patients a better quality of life. The
purpose of this survey is to determine to what extent your
rhinitis interferes with your life and whether it would be improved
by treatment. As with all medical treatment, the information
you provide in this survey will remain strictly confidential.
You may find some of the following questions difficult to answer,
but just answer to the best of your ability.
Nasal and
eye symptoms
0, No
symptoms
1,
Mild
2,
Moderate
3,
Severe
4, Very
severe
fine
Do not fill out the following.
Patient’s name:
Diagnosis:
SAR: (Antigen: ) Treatment (prevention, drug, immunology therapy, operation)
PAR: (Antigen: ) Treatment (prevention, drug, immunology therapy, operation)
Non-Allergy: (Disease:   ) Treatment (   )
Total QOL score
Score by QOL category: 1-5 points daily life
8-10 points social
12, 13 points body
6-7 points out-door
11 points sleep
14-17 points psycho-life
QOL score: None 0, Mild 1, Moderate 2, Severe 3, Very severe 4.
*Please write the names of drugs used if possible
Score: None: 0 points Mild: 1 point Moderate: 2 points Severe: 3 points
Very severe: 4 points
Medical record no: Age: yr
Name of medical
Institution:
Physician’s name: Date:
Sex: M   F
T
o 
be
 c
om
pl
et
ed
 b
y 
ph
ys
ic
ia
n
crying
Runny nose
Sneezing
Blocked nose
(nasal congestion)
Itchy nose
Itchy eyes
Watery eyes
Quality of life 0, No
4, Yes,
very
greatly
2, Yes,
moder-
ately
1, Yes,
slightly
3, Yes,
greatly
1. Reduced productivity at work/home
2. Poor mental concertration
3. Reduced thinking power
4. Impaired reading book/newspaper
5. Reduced memory loss
6. Limitation of outdoor life
 (e.g. sport, picnics)
7. Limitation of going out
8. Hesitation visiting friend or relatives
9. Reduced contact with friends or
others by telephone or conversation
10. Not an easy person to be around
11. Impaired sleeping
12. Tiredness
13. Fatigue
14. Frustration
15. Imitability
16. Depression
17. Unhappiness
Tick the box that best describes the severity of the worst nasal
and eye symptoms you have experienced in the past 1-2 weeks.
Tick the box that best describes the worst extent to which the 
symptoms in I above have interfered with your quality of life
in the past 1-2 weeks. If any of the items listed under Quality of
life below definitely do not relate to the symptoms in I (nose, eye).
then there is no need to tick a box for that particular item.
Please circle the number of the face that best describes your
general state (including your symptoms, life and emotion) in the
past 1-2 weeks.
0 4321
6. Classification of Allergic Rhinitis
Allergic rhinitis is roughly classified based on causa-
tive antigens, predilection time, disease types, and se-
verity of symptoms.
6.1. Predilection Time
Allergic rhinitis is classified into seasonal and peren-
nial. Perennial allergic rhinitis can be caused by some
pollens.
6.2. Disease Types
“Sneezing and rhinorrhea type” is collectively used
because of a strong correlation between sneezing and
rhinorrhea mainly by histamine effect. “Nasal block-
age type” is used for symptoms with more severe na-
sal blockage by mainly by leukotriene effect. Symp-
toms between these types are “combined type.”
6.3. Severity
Determine severity based on symptoms, test results,
and inspection for nasal mucosa. In general, the de-
termined level of severity based on symptoms is im-
portant (Table 2).10
7. Assessment Based on QOL
Allergic rhinitis is manageable when treated, but re-
sists cure. Thus, treatment is aimed at improvement
in quality of life (QOL). A QOL questionnaire for
Japanese with allergic rhinitis was developed in 2002
(Fig. 5).11
8. Treatment of Allergic Rhinitis
8.1. Aim of Treatment
The aim of treatment is to alleviate symptoms and re-
move difficulties with everyday life. Choose a treat-
ment based on severity, disease type, and lifestyle.
8.2. Treatment (Table 3)
8.2.1. Natural courses and communication with
patients
Combinations of pharmacotherapies based on sever-
ity and disease types and communication with pa-
tients improve patients’ satisfaction and QOL. Japa-
nese cedar pollinosis, which developed during child-
hood or early or late middle ages, should be treated
Allergic Rhinitis
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Table　3　Therapy
1. Communication with patients
2. Elimination and avoidance of antigens
- Mites: cleaning, dehumidifi cation, mite control blanket cover, etc.
- Pollen: mask, glasses, etc.
3. Pharmacotherapy
- Chemical mediator receptor antagonists (antihistamine, leukotriene receptor antagonists, anti-prostaglandin D2/throm-
boxane A2 agents) (nasal spray, oral medication)
- Mast cell stabilizer (nasal spray, oral medication)
- Steroids (nasal, oral medication)
- Autonomic drugs (α-sympathomimetics)
- Others
4. Specifi c immunotherapy (conventional, rapid procedures, sublingual)
5. Operative treatment
- Coagulation necrosis (radiofrequency electrocoagulation, laser surgery, trichloroacetic acid chemo-surgery, etc.)
- Resection (corrective surgery of nasal cavity, extensive turbinectomy, nasal polypotomy, etc.)
- Vidian neurotomy and posterior nasal neurotomy
Adapted from reference 1.
in view of a prolonged course.
8.2.2. Elimination and avoidance of antigens (Ta-
ble 4)
In addition to the cleaning, lowering humidity with
dehumidifier is effective in reducing mites. For Japa-
nese cedar pollinosis, refer to pollen dispersal infor-
mation to consider measures to prevent pollen inhala-
tion. For pet allergy, avoid contact with causative pets
and keep dogs and cats clean.
8.2.3. Pharmacotherapy
Therapeutic agents for allergic rhinitis, with different
mechanisms of action, are classified as shown in Ta-
ble 5. Alpha-sympathomimetics (vasoconstrictor nose
drops), which temporarily alleviate nasal blockage,
are also used.
(1) Mast cell stabilizer: Since the development of
disodium cromoglicate (DSCG), local agents (eye
drops and nasal spray) and oral agents, such as tra-
nilast, amlexanox, and pemirolast potassium, have
been on the market. They have mild effects. To
achieve sufficient clinical effects, 2-week prolonged
administration is required. Amelioration rates are in-
creased by continuous administration. Adverse ef-
fects, such as sleepiness and dry mouth, do not oc-
cur.
(2) Chemical mediator receptor antagonists
a) Histamine H1 receptor antagonists (antihista-
mine)
(i) First-generation antihistamine: First-generation
antihistamine often cause adverse effects, such as
sleepiness, impaired performance, and dry mouth,
but have immediate effects on sneezing and watery
rhinorrhea. First-generation antihistamine are contra-
indicated for patients with glaucoma, prostatic hyper-
plasia, and asthma because of their potent anticholin-
ergic effects. They have less central nervous system
depressant actions in children than in adults. Caution
should be exercised for excitatory effects, such as
convulsions. Most of first-generation antihistamine
are marketed as OTC.
(ii) Second-generation antihistamine (Table 6):
Second-generation antihistamine, such as ketotifen
fumarate, oxatomide, azelastine hydrochloride, eme-
dastine difumarate, and mequitazine, are effective to
some extent for nasal blockage aside from sneezing
and watery rhinorrhea. However, they may cause ad-
verse effects, such as sleepiness and impaired per-
formance, in early versions. Thus, caution should be
exercised in administering them. The adverse effects
of late versions, such as epinastine hydrochloride,
ebastine, cetiridine, fexofenadine, loratadine, olopata-
dine hydrochloride, bepotastine besilate, and levo-
cetirizine, have been reduced.12 Priority indications
are mild to moderate sneezing and rhinorrhea type.
Combine them with topical steroids depending on se-
verity. A combination drug containing an antihista-
mine (fexofenadine) and an oral decongestant (pseu-
doephedrine) is now available.
b) Leukotriene receptor antagonists (antileukot-
rienes) (Table 7): Peptide leukotrienes, produced and
released by mast cells, eosinophils, and macro-
phages, have potent relaxing effects on the vascular
smooth muscles of the nasal mucosa, enhancing ef-
fects on vascular permeability, and stimulating effects
on eosinophil migration. Pranlukast and montelukast
are available. They are effective for nasal blockage.
Their effects are increased by prolonged administra-
tion. Comparable effects with those of antihistamines
can be achieved for sneezing and rhinorrhea within 4
weeks.13 Primary indications are treatment of symp-
toms of the moderate or milder nasal blockage type
and those of intermediate type with nasal blockage as
Okubo K et al.
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Table　4　Elimination and avoidance of antigens
<Elimination of house dust mites>
1. For indoor cleaning, use an exhaust circulation-type cleaner.
Clean room for 20 s/m2 twice a week.
2. Avoid using textile sofa, carpet, and tatami wherever possible.
3. Put antimite covers over mattresses, beds, and pillows.
4. Keep humidity at 50% and room temperature at 20-25°C.
<Avoidance of cedar pollen>
1. Collect pollen information.
2. Stay at home during a heavy pollen dispersal period.
3. Shut windows and doors during a heavy pollen dispersal period.
4. When going out during a heavy pollen dispersal period, wear a mask and glasses.
5. When going out, avoid wearing woolen coats.
6. When going home, shake dust off from suit and hair before entering. Wash the face, gargle, and blow your nose.
7. Clean rooms frequently.
<Reduce pet (especially cat) antigens>
1. Stop keeping pets if possible.
2. Keeps pets outdoors and keep them away from bedroom.
3. Clean pets and their environments.
4. Change carpet to fl ooring.
5. Improve ventilation, and clean rooms.
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　5　Therapeutic agents for allergic rhinitis
1. Mast cell stabilizer
Disodium cromoglycate (Intal®), tranilast (Rizaben®), amlexanox (Solfa®), pemirolast potassium (Alegysal®, Pemilaston®)
2. Chemical mediator receptor antagonists
a. Histamine H1 receptor antagonists (antihistamine)
<First-generation>
d-chlorpheniramine maleate (Polaramin®), clemastine fumarate (Tavegyl®), etc.
<Second-generation>
Ketotifen fumarate (Zaditen®), azelastine hydrochloride (Azeptin®), oxatomide (Celtect®), mequitazine (Zesulan®, Nipo-
lazin®), emedastine difumarate (Daren®, Remicut®), epinastine hydrochloride (Alesion®), ebastine (Ebastel®), cetirizine hy-
drochloride (Zyrtec®), levocabastine hydrochloride (Livostin®), bepotastine besilate (Talion®), fexofenadine hydrochloride
(Allegra®), olopatadine hydrochloride (Allelock®), loratadine (Claritin®), fexofenadine & pseudoephedrine (Dellegra®)
b. Leukotriene receptor antagonists
Pranlukast hydrate (Onon®), montelukast sodium (Singulair®, Kipres®)
c. Prostaglandin D2/thromboxane A2 receptor antagonists (anti-prostaglandin D2/thromboxane A2 agents)
Ramatroban (Baynas®)
3. Th2 cytokine inhibitor
Suplatast tosilate (IPD®)
4. Steroids
a. Nasal
Beclomethasone propionate (Aldecin® AQ Nasal, Rhinocort®), fl uticasone propionate (Flunase®), mometasone furoate hy-
drate (Nasonex®), dexamethasone cipecilate capsule for external use (Erizas®)
b. Oral medication
Compounding agent of betamethasone/d-chlorpheniramine maleate (Celestamine®)
5. Others
Nonspecifi c allassotherapy agents, biological preparations, and herbal medicines
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Allergic Rhinitis
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Table　6　Characteristics of second-generation antihistamine (compared with fi rst-generation antihistamine)
1. Few adverse effects, such as central sedation and anticholinergic effects
2. Slightly favorable general improvement
3. Slightly effective for nasal blockage
4. Mild, delayed, and prolonged effects
5. Improvement rate is increased by prolonged administration.
Relatively effective; however, it takes about 2 weeks to achieve sufficient effects in a clinical test on perennial allergic rhinitis. This is the 
time required to suppress hypersensitivity with a single treatment.
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　7　Characteristics of leukotriene receptor antagonists
1. Suppress the vascular dilation and permeability of the nasal mucosa, and improve nasal blockage.
2. More effective for nasal blockage than second-generation antihistamine.
3. Suppress eosinophilic infi ltration and nasal secretion, and improve sneezing and rhinorrhea by ≥2-week prolonged adminis-
tration.
4. Effects are noted at 1 week after start of oral administration, reaching a peak at 4 weeks.
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　8　Characteristics of prostaglandin D2/thromboxane A2 receptor antagonists
1. Suppress the vascular permeability of the nasal mucosa, and improve nasal blockage.
2. More effective for nasal blockage than second-generation antihistamine.
3. Inhibit eosinophil migration caused by PGD2, and improve sneezing and rhinorrhea by ≥2-week prolonged administration.
4. Effects are relatively slow, reaching a peak at 4 weeks.
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　9　Characteristics of nasal steroids
1. Potent effects
2. Relatively rapid effects
3. Few adverse effects
4. Effective equally to the 3 symptoms of nasal allergy
5. Effective only at administration site
Modifi ed from Practical Guideline for the Management of Allergic 
Rhinitis in Japan 2009, digest version.
the chief complaint. No adverse effects of sleepiness,
occur.
c) Prostaglandin D2 and thromboxane A2 receptor
antagonist (Table 8): Ramatroban enhances vascular
permeability in the nasal mucosa and suppresses
eosinophil migration by blocking thromboxane recep-
tors, and suppresses eosinophil migration by block-
ing CRTh2 (chemoattractant receptor-homologous
receptor expressed on Th2 cell), a part of the
prostaglandin D2 receptor. They have strong delayed
effects on nasal blockage.14 Primary indications are
treatment of symptoms of nasal blockage type and
those of combined type with nasal blockage as a chief
complaint. The agents interact with some other medi-
cines, but cause no adverse effects of sleepiness.
(3) Th2 cytokine inhibitors: IPD inhibits the pro-
duction of Th2 cytokines, such as IL-4 and IL-5, in T
lymphocytes to alleviate allergic inflammation. No ad-
verse effects of sleepiness, occur.
(4) Steroids
a) Nasal steroids (Table 9): Beclomethasone
propionate, fluticasone propionate, mometasone fu-
roate, fluticasone furoate, and dexamethasone cipe-
cilate are available. All agents have strong local ef-
fects in small amounts, and are poorly absorbed and
readily degraded. Thus, they have few systemic ad-
verse effects. They are highly effective for sneezing,
watery rhinorrhea, and nasal mucosal swelling, and
exert their effects within 1-3 days. A slight feeling of
nasal irritation, feeling of dryness, and epistaxis may
occur.15
b) Steroids for internal use: Only for intractable
cases with severe nasal blockage and laryngopharynx
symptoms, uncontrollable with nasal spray steroids,
prednisolone (20-40 mgday) can be administered for
4-7 days at the start of treatment. Caution should be
exercised for adverse effects.
(5) Alpha-sympathomimetics (nasal topical vaso-
constrictor [decongestant]): Alpha-sympathomim-
etics act on the α-receptors of vascular smooth mus-
cles to cause vasoconstriction and temporarily allevi-
ate nasal mucosal swelling. Long-term continuous ad-
ministration causes medicament rhinitis. For the
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Table　10　Characteristics of nonspecifi c allassotherapy agents, biological preparations, and herbal medicines
Nonspecifi c allassotherapy agents
Histamine added gamma globulin, bacterial vaccine, and gold preparations are available. They are rarely used alone.
Their mechanisms of action are unclear.
Biological preparations
Neurotropin is commercially available. Its mechanism of action is unclear. They have no instantaneous effect.
Herbal medicines
Syoseiryuto, Kakkonto, Syosaikoto, etc., are used. A placebo-controlled test was conducted only for Syoseiryuto to dem-
onstrate its efficacy.
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　11　Adverse effects of therapeutic agents for allergic rhinitis
Medicines Adverse effects
First-generation antihistamine Sleepiness, systemic malaise, dry mouth, etc. (asthma, dysuria,glaucoma, and contraindication to driving)
Second-generation antihistamine Hepatic and gastrointestinal disorders, sleepiness, and myocardiop-athy for some agents
Oral mast cell stabilizer Hepatic and gastrointestinal disorders, rash, and cystitis for some agents
Leukotriene receptor antagonists Leukopenia, thrombocytopenia, hepatic disorders, rash, diarrhea,abdominal pain, etc.
Prostaglandin D2/thromboxane A2 receptor antagonists
Bleeding tendency, hepatic disorders, rash, abdominal pain, head-
ache, etc.
Th2 cytokine inhibitors Hepatic disorders, jaundice, nephrosis, etc.
Oral corticosteroids
Infection, adrenocortical insufficiency, diabetes, peptic ulcer, moon
face, glaucoma, etc. (contraindicated for treatment of infection, pep-
tic ulcer, hypertension, diabetes, glaucoma, etc.)
Nasal steroids Nasal irritation, feeling of dryness, epistaxis, etc.
Mast cell stabilizer and antihistamine for nasal spray Nasal irritation and sleepiness (for some agents)
Vasoconstrictor nose spray Habituation, rebound phenomena, hyporesponsiveness, etc.
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
most severe pollinosis, they can be administered 2-3
times a day for 1-2 weeks.
(6) Other pharmacotherapy (Table 10): Nonspe-
cific allassotherapy agents, biological preparation,
and herbal medicines can be used.
(7) Adverse effects and drug interactions of thera-
peutic agents for allergic rhinitis (Table 11, 12):
Therapeutic agents for allergic rhinitis are those for
symptomatic treatment, used to alleviate symptoms.
Caution should be exercised for harmful adverse ef-
fects and drug interactions during treatment. If they
occur, take immediate measures and switch to a dif-
ferent treatment.
8.2.4. Specific immunotherapy
Specific immunotherapy has been used over the past
century. Its demonstrated effects may be exerted via
immunological mechanisms. Of note, local mast cells
are decreased, the Th1Th2 balance is altered, and
regulatory T cells are increased. It takes several
months to develop effects, requiring routine injection
for3 years. Furthermore, a systemic anaphylaxis re-
sponse may develop in a small number of cases.16
The characteristics of this method are shown in Ta-
ble 13.
(1) Indications: This therapy is indicated for the
treatment of patients aged 6 years, without severe
systemic symptoms, to whom emergency adrenaline
may be administered. Exclude patients on β-blocker
therapy or with severe asthma. While this therapy
has no harmful effects on pregnant women, it should
not be started during pregnancy.
(2) Implementation
a) Specialists should prescribe antigen extracts and
take measures against systemic reactions, such as
anaphylactic shock.
b) In patients with asthma complications, avoid this
therapy during a paroxysmal period. In patients with
pollinosis, avoid starting this therapy during dispersal
of causative pollen.
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Table　12　Drug interactions of therapeutic agents for allergic rhinitis and measures
Therapeutic agents Concomitant agents Effects Measures
Second-generation 
antihistamine
Alcohol
Sedatives, hypnotics, psy-
chotropics
Cold medicines
Enhanced central inhibition→Hypnosis, 
vertigo, weakness, malaise
Caution should be exer-
cised for combined 
use.→ Reduce dose if 
adverse effects are noted.
Ketotifen fuma-
rate Tolbutamide
Thrombocytopenia→ Bleeding tenden-
cy
Caution should be exer-
cised for combined 
use.→ Discontinue the 
combined use if adverse 
effects are noted.
Oxatomide
Antipsychotics
Tricyclic antidepressants
Digestive function activators
Antiarrhythmics
Exacerbation of extrapyramidal distur-
bances → Tremor and difficulty in walk-
ing
Tricyclic antidepressants
Anticholinergics
Enhanced anticholinergic effects→ Dry 
mouth and exacerbation of glaucoma
β2 stimulants
Theophylline
Exacerbation of tremor
Ebastine Erythromycin
Inhibition of liver drug-metabolizing 
enzymes→ Increased serum carebas-
tine level
Caution should be exer-
cised for combined 
use.→ Reduce dose if 
adverse effects are noted.
Fexofenadine 
hydrochloride
Antacids Decreased absorption→ Reduced ef-fects
Caution should be exer-
cised for combined 
use.→ Discontinue the 
combined use if adverse 
effects are noted.
Erythromycin Increased absorption and decreased clearance→ Increased serum level
Caution should be exer-
cised for combined 
use.→ Reduce dose if 
adverse effects are noted.
Loratadine
Erythromycin
Cimetidine
Inhibition of liver drug-metabolizing en-
zymes → Increased serum levels
Caution should be exer-
cised for combined 
use.→ Reduce dose if 
adverse effects are noted.
Mast cell stabilizer 
Tranilast
Warfarin potassium Inhibition of liver drug-metabolizing enzymes→ Bleeding tendency
Caution should be exer-
cised for combined 
use.→ Discontinue the 
combined use if adverse 
effects are noted.
Leukotriene recep-
tor antagonists
Pranlukast 
hydrate
Itraconazole
Erythromycin
Inhibition of liver drug-metabolizing 
enzymes→ Increased serum levels
Caution should be exer-
cised for combined 
use.→ Reduce the dose 
if adverse effects are not-
ed.
Montelukast Phenobarbital Induction of liver drug-metabolizing enzymes→ Decreased serum levels
Caution should be exer-
cised for combined 
use.→ Increase dose if 
adverse effects are noted.
Prostaglandin D2/
thromboxane A2 
receptor antagonist 
Ramatroban
Antithrombotics Enhanced inhibitory effects on platelet aggregation→ Bleeding tendency Caution should be exer-
cised for combined 
use.→ Discontinue the 
combined use if adverse 
effects are noted.
Aspirin Decline in plasma protein binding → In-creased serum level of free aspirin
Theophylline Competition of liver drug-metabolizing enzymes→ Increased serum levels
Modifi ed from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
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Table　13　Characteristics of specifi c immunotherapy in WHO views report
1. Perform specifi c immunotherapy alone or in combination with a different therapy to treat allergic rhinitis.
2. Effective also for allergic conjunctivitis and allergic asthma.
3. Should be performed by a physician specialized in allergy.
4. Avoid using allergen mixtures for treatment. Use standardized allergen vaccines.
5. Gradually increase allergen to reach maintenance dose.
6. Optimal maintenance dose contains 5-20 μg of a major allergen for each injection.
7. Because of the risks of anaphylaxis, respond appropriately in an emergency.
8. Optimal duration is unknown, generally 3-5 years.
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
Table　14　Operative treatment for allergic rhinitis
1. Surgery to contract and modulate nasal mucosa
Electrocoagulation, cryosurgery, laser surgery, 80% trichloroacetic acid chemo-surgery. Laser surgery is characterized 
by various procedures, instruments, and objectives, such as cauterizing the surface with a laser beam (CO2, semicon-
ductor), evaporating to a deep layer (semiconductor, potassium-titanyl phosphate [KTP]), and widely excising the mu-
cous membrane (KTP).
2. Corrective surgery of nasal cavity to improve nasal ventilation
Submucosal turbinectomy, inferior turbinectomy, septoplasty, Takahashi operation method, extensive turbinectomy, and 
nasal polypotomy.
3. Surgery to improve rhinorrhea
Vidian neurectomy and posterior nasal neurectomy.
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
c) For initial injection, reduce the threshold con-
centration for intradermal reaction to 110. Before in-
jection, ask more than one physicians or health care
professionals about concentration and dosage.
d) Before increasing an aqueous solution concen-
tration or changing lots, conduct an intradermal test.
For patients with erythema of50 mm diameter, care-
fully conduct the test and follow-up the patients for
20-30 minutes after injection.
e) Perform therapy for at least 3 years. Therapeutic
effects often continue for several years after discon-
tinuation of administration.
f) Instruct patients to continue the therapy.
(3) Sublingual immunotherapy (SLIT)
Presently, only the allergen in pollinosis caused by
Japanese cedar pollen is permitted for SLIT in Ja-
pan.17 The current indication is the confirmation of a
positive allergen to Japanese cedar pollen by a skin
reaction or a specific IgE in a patient 12 years of age
or older. The contra-indications are serious illnesses
that require the use of a β blocker, unstable asthma
in which a systemic steroid may be required, treat-
ment with an anti-cancer drug, severe autoimmune
disease, or cases in which it is assumed the treatment
should not be used in the patient because of the side
effects. It cannot be begun from the dispersion pe-
riod. Sublingual inoculation should be suspended in
the case of pregnancy, mouth injury or ulcer, or if
odonto-therapy is required. However, if pregnancy
occurs while this therapy is being administered, aller-
gen immunotherapy, including subcutaneous injec-
tion, is generally thought to be safe.
8.2.5. Surgical treatment
Nasal blockage in allergic rhinitis is often caused by
nasal deformities, such as deviated septum, hy-
pertrophic rhinitis, and nasal polyps. In this case, per-
form corrective surgery of nasal cavity to improve na-
sal ventilation. Before pollen season, laser surgery is
also performed for Japanese cedar pollinosis, but the
effects of this surgery do not continue in the follow-
ing year.18 The main purpose is to alleviate nasal
blockage. Various techniques shown in Table 14 are
used. For intractable rhinorrhea, perform posterior
nasal neurectomy.
8.3. Choice of Therapy
8.3.1. Perennial allergic rhinitis
Select a therapy based on severity and disease type.
Selection criteria are shown in Table 15. For mild
symptoms, second-generation antihistamine, mast
cell stabilizer, or a Th2 cytokine inhibitor is the first-
line agent. For moderate symptoms of sneezing and
rhinorrhea type, choose one of the following: (i)
second-generation antihistamine, (ii) mast cell stabi-
lizer, and (iii) nasal topical steroids. Add (i) or (ii)
with (iii) as needed. For symptoms of nasal blockage
or combined type, choose an agent from (i) leukot-
riene receptor antagonists, (ii) prostaglandin D2
thromboxane A2 receptor antagonist, (iii) Th2 cy-
tokine inhibitor, (iv) nasal topical steroids. Combine
(i) or (ii) or (iii) with (iv) as needed.
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Table　15　Treatment of perennial allergic rhinitis
Severity Mild Moderate Severe
Disease types
Sneezing and rhinor-
rhea type
Nasal blockage type 
or combined type 
with nasal blockage 
as a chief complaint
Sneezing and 
rhinorrhea type
Nasal blockage type or 
combined type with 
nasal blockage as a
chief complaint
Treatments
a. Second-
generation 
antihista-
mine
b. (Mast cell) 
stabilizer
c. Th2 cytokine 
inhibitors
a. Second-generation 
antihistamine
b. (Mast cell) stabilizer
c. Th2 cytokine inhibi-
tors
d. Nasal steroids
a. Anti-LTs agents
b. Anti-PGD2/TXA2 
agents
c. Nasal steroids
Nasal steroids 
+ Second-gen-
eration antihis-
tamine
Nasal steroids + Anti-
LTs agents or anti-
PGD2/TXA2 agents
Choose one of 
(a), (b), (c).
Choose one of (a), (b), 
(c), and (d). Combine 
(a), (b), or (c), with (d), 
as needed.
Choose one of (a), 
(b), and (c). Com-
bine (a) or (b) with (c) 
as needed.
Use vasoconstrictor 
nasal spray for only 
5-7 days at the start of 
treatment as needed.
Perform surgery for cases with nasal de-
formities of a nasal blockage type.
Specifi c immunotherapy
Elimination and avoidance of antigens
Note 1) Second-generation antihistamine are often used. First-generation antihistamine are inexpensive, rapidly effective, and short-act-
ing agents, and are used as such. However, avoid their use for those with severe sleepiness, urination disorder, glaucoma, or asthma.
Note 2) Stabilizer = Mast cell stabilizer, Anti-LTs agents = Leukotriene receptor antagonists, Anti-PGD2/TXA2 agents = Prostaglandin D2/
Thromboxane A2 receptor antagonists.
Note 3) For severe nasal blockage, use vasoconstrictor nose drops for ≤1 week.
Note 4) Use one or more agents depending on symptoms.
Note 5) Even if symptoms are alleviated, do not discontinue the agent immediately, but confi rm stability for several months to reduce dose 
gradually.
Note 6) For severe cases unresponsive to the above agents, oral corticosteroids may have to be used for a short period (1-2 weeks).
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
For severe cases with severe sneezing and rhinor-
rhea, combine second-generation antihistamine with
nasal spray steroids. For symptoms of nasal blockage
or combined type, add nasal topical steroids with leu-
kotriene receptor antagonists or prostaglandin D2
thromboxane A2 receptor antagonists. For all cases,
eliminate and avoid antigens. For cases in which
treatment can be continued, specific immunotherapy
can also be chosen. For cases of nasal blockage type,
in which the effects of pharmacotherapy are insuffi-
cient, surgical treatment can also be chosen.
8.3.2. Pollinosis
Therapy is chosen based on severity and disease
type. However, the severity of pollinosis markedly
changes with the amount of pollen dispersal. There-
fore, before starting treatment, determine the sever-
ity based on symptoms at a hospital visit, symptoms
at peak pollen dispersal, and amounts of pollen dis-
persal (Table 16).
(1) Primal therapy (primary care) (Fig. 6): The aim
of primary care is to suppress allergic inflammation
and nasal mucosal hypersensitivity, which are aggra-
vated by repeated exposure to small amounts of anti-
gen. For patients who suffer from even mild symp-
toms simultaneously with or before pollen dispersal,
start pharmacotherapy when symptoms develop. Ad-
minister second-generation antihistamine or mast cell
stabilizer for symptoms of sneezing and rhinorrhea
type. Administer leukotriene receptor antagonists, a
prostaglandin D2thromboxane A2 receptor antago-
nist, or a Th2 cytokine inhibitor for symptoms of na-
sal blockage type and those of combined type with
nasal blockage as a chief complaint.19 If symptoms
are exacerbated as pollen dispersal increases, use the
combination of nasal topical steroids early.
(2) Mild symptoms: For mild symptoms, adminis-
ter second-generation antihistamine or a mast cell
stabilizer. If symptoms are exacerbated, concomi-
tantly use nasal topical steroids early.
(3) Moderate symptoms: For symptoms of sneez-
ing and rhinorrhea type, start treatment by the com-
bination of second-generation antihistamine and nasal
topical steroids. For symptoms of nasal blockage
type, use a combination of leukotriene receptor an-
tagonists or prostaglandin D2thromboxane A2 re-
ceptor antagonist and nasal topical steroids. For
symptoms of combined type, add second-generation
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Fig.　6　Primal therapy for Japanese cedar pollinosis. Adapted from Practical Guideline for the 
Management of Allergic Rhinitis in Japan 2009, digest version.
First date of
observation
Start date of
pollen
dispersal
End date of
pollen
dispersal
Pollen dispersal, hypersensitivity, and symptoms
Effects of primal therapy (primary care)
Severity of
symptoms Hypersensitivity
Pollen
dispersal
Severe
Mild Hypersensitivity
Symptoms during
primal therapy
Table　16　Choice of therapy for pollinosis based on severity
Severity Primal therapy Mild Moderate Severe
Disease 
types
Sneezing and 
rhinorrhea type
Nasal blockage 
type or com-
bined type with 
nasal blockage 
as a chief com-
plaint
Sneez ing  and 
rhinorrhea type
Nasa l  b l ockage
type  or  combined 
type with nasal
blockage as a chief 
complaint
Treatments
a. Second-genera-
tion antihista-
mine
b. Stabilizer
c. Th2 cytokine 
inhibitors
d. Anti-LTs agents
e. Anti-PGD2/TXA2 
agents
a. Second-
generation 
antihista-
mine
b. Nasal 
steroids
Second-gener-
ation antihista-
mine + Nasal 
steroids
Anti-LTs agents 
or Anti-PGD2/
TXA2 agents + 
Nasal steroids + 
Second-genera-
tion antihista-
mine
Nasal steroids + 
Second-genera-
t ion ant ih is ta-
mine
Nasal steroids +
Anti-LTs agents or 
An t i -PGD 2/TXA 2 
agents + Second-
generation antihis-
tamine
Choose one of (a), 
(b) for sneezing 
and rhinorrhea 
type, and (c), (d), 
(e) for nasal block-
age type and com-
bined type
Start treatment 
with (a) and 
eye drops, and 
add  (b) as 
needed.
Use vasoconstrictor
nasal spray for only
7-10 days at the 
start of treatment as
needed. For cases 
with severe nasal
blockage, treatment 
may be started with 
oral corticosteroid
administration for 
4-7 days.
Antihistamine for eye drops or stabilizer Antihistamine for eye drops, stabilizer, 
or steroids
Perform surgery for cases with nasal 
deformities of a nasal blockage type.
Specifi c immunotherapy
Elimination and avoidance of antigens
Note) Stabilizer = mast cell stabilizer, Anti-LTs agents = Leukotriene receptor antagonists, Anti-PGD2/TXA2 agents = Prostaglandin D2/
Thromboxane A2 receptor antagonists.
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
antihistamine.
(4) Severe and the most severe cases: For symp-
toms of sneezing and rhinorrhea type, use a combina-
tion of nasal topical steroids and second-generation
antihistamine. For symptoms of the nasal blockage
type and those of combined type, add leukotriene re-
ceptor antagonists or a prostaglandin D2thrombox-
ane A2 receptor antagonist. For cases with severe na-
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sal blockade, concomitantly administer nasal topical
vasoconstrictor to start treatment. For cases with se-
vere nasal mucosal swelling and severe pharyngeal
and laryngeal symptoms at hospital visit, administer
oral corticosteroids for up to 4-7 days. Start treatment
by the combination of nasal topical steroids, second-
generation antihistamine, and leukotriene receptor
antagonists.
9. Points to Remember in Treating Compli-
cations
9.1. Acute and Chronic Sinusitis
In patients with allergic rhinitis, imaging tests may
show opacities in the paranasal sinuses. Diagnose
them as sinusitis complications. It is controversial
whether sinusitis occurs in patients with type I al-
lergy. Among children, particularly infants, infectious
sinusitis, including an acute one, is common, which
requires composite treatment. Allergic inflammation
is characterized by transparent and watery or viscous
rhinorrhea. Differential diagnosis of early infection is
difficult because of serous and watery rhinorrhea.
Mucin and neutrophils increase as prophylaxis reac-
tions progress, resulting in viscosity increase of rhi-
norrhea. Epithelial detachment causes the accumula-
tion of neutrophils and bacteria, resulting in purulent
or yellow-green rhinorrhea. For cases with nasal dis-
charge eosinophilia, consider allergic rhinitis. How-
ever, in most cases with neutrophils coexisting or
predominating, symptoms cannot be improved by al-
lergy therapy alone. Thus, sinusitis should be diag-
nosed and treated. Conduct X-ray examination (Cald-
well and Waters methods) to check opacities in the
paranasal sinuses. In some cases, causative bacteria
should be identified from the bacterial cultures of rhi-
norrhea or upper pharynx. For acute bacterial sinusi-
tis, administer an oral antimicrobial, amoxicillin, as a
first-line agent. For neutrophil dominant chronic si-
nusitis, 14-membered ring macrolides are effective
when long-term administered in small amounts. Cau-
tion should be exercised for the combination of theo-
phylline and 14-membered ring macrolides because
serum theophylline levels may rise and cause poison-
ing symptoms.
9.2. Eosinophilic Sinusitis
Some patients with chronic sinusitis present with
massive submucosal eosinophilic infiltration. Eosino-
philic sinusitis is characterized by multiple nasal pol-
yps, viscous rhinorrhea, and olfactory disorder, and is
often complicated by asthma. Eosinophilic sinusitis is
extremely intractable and resistant to surgery, result-
ing in repeated relapses. Oral corticosteroid therapy
often results in a complete response. Eosinophilic oti-
tis media is a frequent complication. Eosinophilic oti-
tis media is characterized by an accumulation of
sticky viscous liquid in the middle ear. Eosinophilic
otitis media is an intractable disease characterized by
eosinophilic infiltration in the accumulated liquid.
Hearing loss is often exacerbated. Tinnitus and aural
fullness cause severe discomfort. The symptoms of
asthma complications, particularly asthma attack, are
often exacerbated. Systemic or intratympanic steroid
administration is effective.
9.3. Correlation Between Asthma and Allergic
Rhinitis or Eosinophilic Sinusitis in View of One
Airway One Disease
Approximately 30% of patients with allergic rhinitis
are complicated by asthma. Reportedly, 28%-85% of
patients with asthma are complicated by allergic
rhinitis. Additionally, 75% of patients with atopic
asthma and 40% of patients with nonatopic asthma are
complicated by allergic rhinitis. Most patients with al-
lergic rhinitis present with bronchial hyperreactivity.
This also suggests that allergic rhinitis is a risk factor
for asthma. The contribution rate of eosinophilic si-
nusitis to the severity of asthma is 34.5%. Eosinophilic
sinusitis is fundamental to considering the pathology
and treatment of asthma. Antigens, induced in the na-
sal mucosa, increase intercellular adhesion molecules
and eosinophils in the lower respiratory tract, and ex-
acerbate airway hyperresponsiveness.20 In contrast,
among patients with asthma, complicated by allergic
rhinitis, those who underwent treatment for allergic
rhinitis showed significantly reduced emergency vis-
its and hospitalization as compared with those who
were not treated. Surgical treatment (endoscopic si-
nus surgery) or medication for eosinophilic sinusitis
or nasal polyp improves pulmonary functions. Thus,
to diagnose patients with asthma complicated by al-
lergic rhinitis or eosinophilic sinusitis, examine both
upper and lower respiratory tracts. Examine the pa-
thology in view of “one airway and one disease” to un-
derstand their correlation. Take an approach based
on the correlation.21
9.4. Treatment of Sinusitis in Patients With Aspi-
rin Intolerance
In treating eosinophilic sinusitis in patients with aspi-
rin intolerance, avoid using analgesics, antipyretics
and antiinflammatory drugs (nonsteroidal antiinflam-
matory drugs [NSAIDs]) because they may cause an
asthmatic attack. Basic antiinflammatory drugs cause
no, or mild if any, asthmatic attacks. If pain occurs af-
ter surgery for sinusitis, pentazocine can be injected
intramuscularly. Intravenous injection of hydrocorti-
sone may exacerbate asthma. This may be caused by
succinic acid ester contained in the injection. If corti-
costeroids are used for injection, choose betametha-
sone sodium phosphate.
9.5. Allergic Conjunctivits
Allergic conjunctivitis includes hyperemic conjuncti-
vitis and vernal keratoconjunctivitis (proliferative con-
junctivitis). Atopic keratoconjunctivitis, complicated
Okubo K et al.
372 Allergology International Vol 63, No3, 2014 www.jsaweb.jp
Table　17　Risks of medication in pregnant women with allergic rhinitis
Generic name Trade name Australian standards FDA standards
Antiallergics (for internal use)
d-chlorpheniramine maleate Polaramin® A B
d-chlorpheniramine maleate Allergin® A B
Diphenhydramine hydrochloride Vena®, Restamin® A B
Cyproheptadine hydrochloride Periactine® A B
Promethazine hydrochloride Pyrethia®, Hiberna® C
Clemastine fumarate Tavegyl® A B
Diphenylpyraline teoclate Agiell®, Plokon® B2
Loratadine Claritin® B1 B
Cetirizine hydrochloride Zyrtec® B2 B
Fexofenadine hydrochloride Allegra® B2 C
Amlexanox Solfa® B
Epinastine hydrochloride Alesion® C
Azelastine hydrochloride Azeptin® C
Ketotifen fumarate Zaditen® C
Nasal sprays
Beclomethasone propionate Aldecin® AQ Nasal, Rhinocort® B3 C
Fluticasone propionate Flunase® B3 C
Disodium cromoglycate Intal® B
Amlexanox Solfa® B
Ketotifen fumarate Zaditen® C
Adapted from Practical Guideline for the Management of Allergic Rhinitis in Japan 2009, digest version.
by atopic dermatitis, has also become common as the
number of patients with atopic dermatitis increases.
Hyperemic conjunctivitis is a common complication.
Complications are common among patients with polli-
nosis. Most patients with pollinosis suffer from ocular
itching, lacrimation, hyperemia, eye discharge, etc.
Severe symptoms cause eyelid swelling. When chil-
dren rub their eyes with their hands, they cause dark
circles to form under their eyes. Eye discharge
shows eosinophilia. Eosinophilia can be detected only
by scratching the conjunctiva.
For pollinosis, wear glasses and avoid wearing con-
tact lens if possible. For prolonged administration of
steroid eye drops, caution should be exercised for ad-
verse effects, such as glaucoma and corneal ulcer.
Eye irrigation is effective in eliminating pollen.22
10. Precautions
10.1. Precautions for Pregnant Women (Table
17)
During pregnancy, congestive and allergic rhinitis
often occurs, and symptoms are exacerbated. Con-
sider the impact of medication to pregnant and
breast-feeding women on their fetuses and infants.
For the 4.5 months between early pregnancy and or-
ganogenesis in particular, perform treatment only
when benefits outweigh risks. For nasal blockage, hy-
perthermia, bathing, steamed towel, and masks are
effective. If medication is required after the fourth
month of pregnancy, minimize the use of local
agents, such as DSCG, nasal spraymast cell stabilizer,
nasal spray antihistamine, and nasal topical steroids.
10.2. Precautions for Children
Allergic rhinitis is common among male infants, often
complicated by atopic dermatitis and asthma. Al-
though it is less common than atopic dermatitis and
asthma, allergic rhinitis may heal spontaneously. Se-
vere nasal itching and nasal blockade often cause na-
sal rubbing and facial movements and alterations
(dark circle under the eyes [allergic shiner] and hori-
zontal lining on the tip of the nose). Since children
have large adenoids, palates, and tonsils, caution
should be exercised for various infections. Childhood
allergic rhinitis is generally intractable and requires
long-term treatment. Thus, avoid irresponsible treat-
ment and frequent hospital visits. Allergic rhinitis
may be exacerbated by cold syndromes. Mite allergy
is common among children. Eliminate and avoid
mites, and instruct children to stay away from pets.
Pharmacotherapy for adults is also indicated for
children. However, few therapeutic agents are indi-
cated for the treatment of childhood allergic rhinitis.
For elementary and junior high school students, give
half the adult dose. Perform specific immunotherapy
for patients aged6 years. For asthma complications,
carefully adjust the antigen dose. Perform surgery to
improve nasal ventilation only for senior elementary
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Fig.　7　Classifi cation of allergic rhinitis by ARIA. Modifi ed from ARIA 2008, Japanese ver-
sion.
Intermittent symptoms
- <4 days a week
- or <4 weeks
Persistent symptoms
- ≥4 days a week
- and ≥4 weeks
Mild
- Normal sleep
- No trouble with daily life, sport,
and leisure
- No trouble with working and study
- No troublesome symptoms
Moderate/Severe
One or more items of the following:
- Sleep disorder
- Disturb daily life, sport, and leisure
- Symptoms occur at workplace or
school
- Troublesome symptoms
students.
10.3. Oral Allergy Syndrome
Oral allergy syndrome (OAS) is an IgE antibody-
dependent immediate food allergy, which causes hy-
persensitivity in the oropharyngeal mucosa and local
and systemic type I allergic reactions after ingestion
of food. OAS is often complicated by pollinosis or la-
tex allergy. Potential allergens include cross reacting
molecules, which is common between pollen anti-
gens or latex allergens of fruits, vegetables, and cere-
als and causative food allergens of OAS. In patients
with allergies to the pollens of Betula platyphyla, Ro-
saceae fruits (e.g., apples and peaches) cause fre-
quently OAS. Reportedly, the common causative
foods of OAS are tomato, melon, watermelon, and or-
ange in patients with grass pollinosis. In patients with
mugwort and ragweed pollinosis, the common causa-
tive foods are melon, watermelon, and celery. Melon,
watermelon, and kiwi fruit are relatively common
causative foods. In patients with latex allergy, avo-
cado, chestnut, banana, and kiwi fruit are the com-
mon causative foods of OAS. In patients with Japa-
nese cedar pollinosis, OAS caused by tomato has
been reported. In most patients with OAS, local symp-
toms, such as itching, tingling, and edematous swel-
ling on the oropharyngeal mucosa and lips, occur
within 15 minutes after food ingestion. Digestive
symptoms, such as diarrhea and abdominal pain, la-
ryngeal edema, watery rhinorrhea, and conjunctival
hyperemia also occur. Systemic symptoms include
urticaria, eczema-like cutaneous symptoms, asth-
matic symptoms, and sometimes anaphylactic shock.
Avoiding causative food intake is the only the reliable
treatment.
10.4. Relationship with Aria (Allergic Rhinitis
and Its Impact on Asthma)
In 2001, allergy researchers from many countries
published a consensus report, “Allergic Rhinitis and
its Impact on Asthma (ARIA)” with WHO’s recom-
mendation.21 This is sometimes considered as a stan-
dard international guideline for allergic rhinitis. As
the title indicates, allergic rhinitis is examined re-
garding the effects on asthma. Hereinafter, major dif-
ferences from the Practical Guideline for the Manage-
ment of Allergic Rhinitis in Japan are described.
10.4.1. Classification of rhinitis
In the Japanese guideline, rhinitis is classified based
on pathology. In the ARIA2008, rhinitis is classified
based on causes, with some diseases overlapping
(Fig. 7).
10.4.2. Classification of pathology
In the Japanese guideline, rhinitis is roughly divided
into perennial and seasonal rhinitis based on the
causative antigens of allergic diseases. In the ARIA
2008, rhinitis is divided into persistent symptoms,
which continue 4 days a week for 4 weeks a year,
and intermittent symptoms, which continue <4 days a
week for <4 weeks a year. Behind this background,
there are multiple sensitizations and a confusing clas-
sification of perennial and seasonal rhinitis symp-
toms. However, Japanese cedar pollinosis and peren-
nial mite allergic rhinitis, which affect most Japanese
patients with rhinitis, are similarly classified as persis-
tent rhinitis.
10.4.3. Classification of severity
In the ARIA2008, rhinitis is simply classified into
“mild symptoms” and “moderatesevere symptoms.”
This classification is based on patients’ assessments
Okubo K et al.
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Fig.　8　Step-by-step approach for treatment by ARIA. Modifi ed from ARIA 2008, Japanese version.
For conjunctivitis, add the following agents:
- Oral histamine H1 antagonists, or intraocular histamine H1 antagonists, or intraocular disodium cromoglycate
(or eye irrigation with physiological saline).
Addition or dose
increase of nasal
steroids
For rhinorrhea,
add ipratropium.
Reconsider diagnosis.
Reconfirm compliance.
Suspect infection and
others causes.
No effects: Gradually
increase dose.
Improved: Continue the
administration for
1 month.
For perennial rhinitis,
revisit a hospital at
2-4 weeks.
- Oral histamine H1
antagonists
- Nasal histamine H1
antagonists and/or
vasoconstrictors/
leukotriene receptor
antagonists
(in random order)
Mild Mild
Intermittent symptoms Persistent symptoms
Avoidance of antigens
Diagnosis of allergic rhinitis
(History: prick test or serum specific IgE antibody)
(adolescence and adult)
Moderate
Severe
- Oral histamine H1
antagonists
- Nasal histamine H1
antagonists and/or
vasoconstrictors/nasal
steroids/leukotriene
receptor antagonists
(in random order)
Moderate
Severe
Nasal steroids
Reexamined at
2-4 weeks.
Improved
Gradually reduce the
dose and continue
administration for
1 month.
No effects
No effects
Surgery is recommended.
For itching/sneezing,
add histamine H1
antagonists.
For blockage, add
vasoconstrictors or
oral corticosteroids
(for a short time).
Consider specific immunotherapy.
Improved: Step down
Exacerbated: Step up
regarding influences on sleep, everyday life, work,
etc. Behind this background, QOL assessment is em-
phasized. In the Japanese guideline, most patients
who visit medical institutions are classified as having
moderate or more severe symptoms. Thus, ARIA2008
classification is unsuitable for actual treatment.
10.4.4. Treatments (Fig. 8)
Treatments are simply described because of the sim-
ple classification of allergic rhinitis. For example, for
persistent moderatesevere symptoms, the main
therapeutic targets in this classification, first adminis-
ter nasal spray steroids, and if the symptoms are not
improved within 2-4 weeks, increase the dosage or
Allergic Rhinitis
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use different agents. Most patients with Japanese ce-
dar pollinosis are classified into severe diseases ac-
cording to the Japanese guideline. Because of expo-
sure to large amounts of pollen, treating these pa-
tients with a single agent is often difficult. Thus, de-
scriptions that are more detailed are needed.
The ARIA2008 provides sufficient descriptions to
allow the understanding of pathology, evidence of the
therapy, etc. However, important issues in the ARIA
2008, such as cost-benefit and the establishing evi-
dence for inapplicable therapies to Japanese circum-
stances, where characteristic pollinosis like Japanese
cedar pollinosis exists, should be examined in Japan.
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